Company profile: Sage Therapeutics
1.1 - Company Overview
Company description
- Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
Products and services
- ZULRESSO: An injectable formulation treating postpartum depression in patients 15 years and older, delivered as a therapy specifically indicated for this condition
- ZURZUVAE: An oral formulation for adults with postpartum depression, administered over a 14-day period as a prescribed regimen for this condition
- SAGE-689: An investigational-stage drug candidate evaluated for acute GABA hypofunction, with development centered on this specific neurotransmission deficiency in acute states
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sage Therapeutics
Reunion Neuroscience
HQ: Canada
Website
- Description: Provider of clinical-stage therapeutic solutions for underserved mental health conditions, developing RE104, a proprietary short-duration serotonergic psychedelic therapy for postpartum depression and other mental health disorders, and RE200s, discovery candidates structurally similar to classic psychedelics designed to selectively target the serotonin 2A receptor without off-target effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reunion Neuroscience company profile →
iZumi Bio
HQ: United States
Website
- Description: Provider of biotechnology solutions leveraging cellular reprogramming, including induced pluripotent stem cells and directed differentiation, to develop stem cell-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iZumi Bio company profile →
Aelis Farma
HQ: France
Website
- Description: Provider of signaling-specific therapeutics targeting GPCRs, notably the CB1 receptor, including AEF0117 for cannabis-related disorders, AEF0217 for cognitive deficits (initially Down syndrome, with potential for Fragile X syndrome and aging), and CB1-SSi inhibitors that selectively inhibit pathological CB1 hyperactivity without affecting normal brain functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aelis Farma company profile →
VeriNOS Pharma
HQ: Germany
Website
- Description: Provider of innovative therapeutics under clinical development for cerebral diseases, focusing on traumatic brain injury. Develops drugs inhibiting a defined cascade. Product Ronopterin, a selective iNOS inhibitor, reduces brain damage and improves outcomes in traumatic brain injury, neuro-oncology, and diabetic retinopathy by decreasing glutamate and radical production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VeriNOS Pharma company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sage Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sage Therapeutics
2.2 - Growth funds investing in similar companies to Sage Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sage Therapeutics
4.2 - Public trading comparable groups for Sage Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →